JP2006508326A - 乳癌を検出するためのバイオマーカーの使用 - Google Patents
乳癌を検出するためのバイオマーカーの使用 Download PDFInfo
- Publication number
- JP2006508326A JP2006508326A JP2003575071A JP2003575071A JP2006508326A JP 2006508326 A JP2006508326 A JP 2006508326A JP 2003575071 A JP2003575071 A JP 2003575071A JP 2003575071 A JP2003575071 A JP 2003575071A JP 2006508326 A JP2006508326 A JP 2006508326A
- Authority
- JP
- Japan
- Prior art keywords
- marker
- biomarker
- sample
- biomarkers
- capture reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 198
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 97
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 167
- 238000012360 testing method Methods 0.000 claims abstract description 94
- 241001465754 Metazoa Species 0.000 claims abstract description 82
- 239000003550 marker Substances 0.000 claims description 398
- 239000000523 sample Substances 0.000 claims description 226
- 206010028980 Neoplasm Diseases 0.000 claims description 165
- 108090000623 proteins and genes Proteins 0.000 claims description 139
- 102000004169 proteins and genes Human genes 0.000 claims description 136
- 201000011510 cancer Diseases 0.000 claims description 135
- 238000001514 detection method Methods 0.000 claims description 57
- 238000000018 DNA microarray Methods 0.000 claims description 54
- 210000002966 serum Anatomy 0.000 claims description 45
- 239000003153 chemical reaction reagent Substances 0.000 claims description 41
- 238000004949 mass spectrometry Methods 0.000 claims description 31
- 239000000758 substrate Substances 0.000 claims description 25
- 238000009739 binding Methods 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 21
- 238000003018 immunoassay Methods 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000002184 metal Substances 0.000 claims description 12
- 229910052751 metal Inorganic materials 0.000 claims description 12
- 210000002381 plasma Anatomy 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 230000000717 retained effect Effects 0.000 claims description 7
- 239000012805 animal sample Substances 0.000 claims description 4
- 239000013522 chelant Substances 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 238000003499 nucleic acid array Methods 0.000 claims description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 abstract description 19
- 238000005259 measurement Methods 0.000 abstract description 14
- 239000000107 tumor biomarker Substances 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 description 126
- 150000002500 ions Chemical class 0.000 description 63
- 239000003463 adsorbent Substances 0.000 description 55
- 241000282414 Homo sapiens Species 0.000 description 46
- 239000012071 phase Substances 0.000 description 45
- 239000007789 gas Substances 0.000 description 44
- 238000001228 spectrum Methods 0.000 description 40
- 238000004458 analytical method Methods 0.000 description 38
- 238000003745 diagnosis Methods 0.000 description 32
- 239000000203 mixture Substances 0.000 description 26
- 238000003795 desorption Methods 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 238000000926 separation method Methods 0.000 description 20
- 239000003480 eluent Substances 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 239000012491 analyte Substances 0.000 description 17
- 238000004422 calculation algorithm Methods 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 239000013610 patient sample Substances 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 238000001616 ion spectroscopy Methods 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 15
- 239000002131 composite material Substances 0.000 description 13
- 238000010586 diagram Methods 0.000 description 13
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 13
- 238000004587 chromatography analysis Methods 0.000 description 11
- 238000013145 classification model Methods 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000003491 array Methods 0.000 description 10
- 238000009826 distribution Methods 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000007477 logistic regression Methods 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000003595 spectral effect Effects 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 7
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000012549 training Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 239000013060 biological fluid Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000007562 Serum Albumin Human genes 0.000 description 5
- 108010071390 Serum Albumin Proteins 0.000 description 5
- 238000005571 anion exchange chromatography Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 5
- 238000010208 microarray analysis Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- KEJYUAMBFQZVEH-UHFFFAOYSA-N 3-cyano-2-hydroxy-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(O)=C(C#N)C1=CC=CC=C1 KEJYUAMBFQZVEH-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 208000011803 breast fibrocystic disease Diseases 0.000 description 4
- 238000007635 classification algorithm Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000005684 electric field Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 108091005608 glycosylated proteins Proteins 0.000 description 4
- 102000035122 glycosylated proteins Human genes 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012474 protein marker Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000004630 atomic force microscopy Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- HJMZMZRCABDKKV-UHFFFAOYSA-N carbonocyanidic acid Chemical compound OC(=O)C#N HJMZMZRCABDKKV-UHFFFAOYSA-N 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002790 cross-validation Methods 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000000572 ellipsometry Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000003909 pattern recognition Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000003498 protein array Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012465 retentate Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000080590 Niso Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241001495084 Phylo Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000012952 Resampling Methods 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000000091 biomarker candidate Substances 0.000 description 2
- 201000005389 breast carcinoma in situ Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 2
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002848 electrochemical method Methods 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 208000030776 invasive breast carcinoma Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000005040 ion trap Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000009607 mammography Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000009149 molecular binding Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000012628 principal component regression Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000001920 surface-enhanced laser desorption--ionisation mass spectrometry Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 229910001428 transition metal ion Inorganic materials 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010006189 Breast cancer in situ Diseases 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- ORLJVINATUKLJQ-UHFFFAOYSA-N C1C(CCCC2)C2=CC1 Chemical compound C1C(CCCC2)C2=CC1 ORLJVINATUKLJQ-UHFFFAOYSA-N 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000012774 diagnostic algorithm Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001871 ion mobility spectroscopy Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 210000000019 nipple aspirate fluid Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010238 partial least squares regression Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 238000000756 surface-enhanced laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36247302P | 2002-03-06 | 2002-03-06 | |
| PCT/US2003/006850 WO2003076896A2 (en) | 2002-03-06 | 2003-03-06 | Use of biomarkers to detect breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508326A true JP2006508326A (ja) | 2006-03-09 |
| JP2006508326A5 JP2006508326A5 (enExample) | 2006-04-20 |
Family
ID=27805178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003575071A Pending JP2006508326A (ja) | 2002-03-06 | 2003-03-06 | 乳癌を検出するためのバイオマーカーの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050170352A1 (enExample) |
| EP (1) | EP1585962A4 (enExample) |
| JP (1) | JP2006508326A (enExample) |
| AU (1) | AU2003217954A1 (enExample) |
| CA (1) | CA2478036A1 (enExample) |
| WO (1) | WO2003076896A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009236908A (ja) * | 2008-03-04 | 2009-10-15 | Kazuhiro Imai | 乳癌の診断及び治療法 |
| JP2011254810A (ja) * | 2010-05-12 | 2011-12-22 | En Otsuka Pharmaceutical Co Ltd | クローン病の活動性の分類 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2580494A1 (en) * | 2004-09-17 | 2006-03-30 | The Johns Hopkins University | Biomarkers for breast cancer |
| GB0514553D0 (en) | 2005-07-15 | 2005-08-24 | Nonlinear Dynamics Ltd | A method of analysing a representation of a separation pattern |
| GB0514555D0 (en) * | 2005-07-15 | 2005-08-24 | Nonlinear Dynamics Ltd | A method of analysing separation patterns |
| CA2653398A1 (en) * | 2006-05-26 | 2007-12-06 | Board Of Regents, The University Of Texas System | Reverse phase protein array, protein activation and expression signatures, and associated methods |
| US8026108B1 (en) * | 2006-10-19 | 2011-09-27 | The University Of Central Florida Research Foundation, Inc. | Detection of biotargets using bioreceptor functionalized nanoparticles |
| JP5219440B2 (ja) * | 2007-09-12 | 2013-06-26 | キヤノン株式会社 | 測定装置 |
| WO2009086297A2 (en) * | 2007-12-21 | 2009-07-09 | The Board Of Regents Of The University Of Oklahoma | Identification of biomarkers in biological samples and methods of unsing same |
| US8666673B2 (en) * | 2010-05-14 | 2014-03-04 | Biomerieux, Inc | Identification and/or characterization of a microbial agent using taxonomic hierarchical classification |
| WO2018069891A2 (en) * | 2016-10-13 | 2018-04-19 | University Of Florida Research Foundation, Inc. | Method and apparatus for improved determination of node influence in a network |
| US10380739B2 (en) * | 2017-08-15 | 2019-08-13 | International Business Machines Corporation | Breast cancer detection |
| CN110824166A (zh) * | 2019-11-20 | 2020-02-21 | 淄博市中心医院 | 一种便捷的肿瘤标志物分子检测方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5855889A (en) * | 1995-05-31 | 1999-01-05 | Washington University | Mammaglobin, a mammary-specific breast cancer protein |
| US6703204B1 (en) * | 2000-07-28 | 2004-03-09 | The Brigham & Women's Hospital, Inc. | Prognostic classification of breast cancer through determination of nucleic acid sequence expression |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936424B1 (en) * | 1999-11-16 | 2005-08-30 | Matritech, Inc. | Materials and methods for detection and treatment of breast cancer |
| AUPQ886100A0 (en) * | 2000-07-19 | 2000-08-10 | Biotron Limited | Diagnostic test |
-
2003
- 2003-03-06 US US10/506,725 patent/US20050170352A1/en not_active Abandoned
- 2003-03-06 AU AU2003217954A patent/AU2003217954A1/en not_active Abandoned
- 2003-03-06 EP EP03713930A patent/EP1585962A4/en not_active Ceased
- 2003-03-06 CA CA002478036A patent/CA2478036A1/en not_active Abandoned
- 2003-03-06 JP JP2003575071A patent/JP2006508326A/ja active Pending
- 2003-03-06 WO PCT/US2003/006850 patent/WO2003076896A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5855889A (en) * | 1995-05-31 | 1999-01-05 | Washington University | Mammaglobin, a mammary-specific breast cancer protein |
| US6703204B1 (en) * | 2000-07-28 | 2004-03-09 | The Brigham & Women's Hospital, Inc. | Prognostic classification of breast cancer through determination of nucleic acid sequence expression |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009236908A (ja) * | 2008-03-04 | 2009-10-15 | Kazuhiro Imai | 乳癌の診断及び治療法 |
| JP2011254810A (ja) * | 2010-05-12 | 2011-12-22 | En Otsuka Pharmaceutical Co Ltd | クローン病の活動性の分類 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1585962A4 (en) | 2009-03-18 |
| WO2003076896A2 (en) | 2003-09-18 |
| AU2003217954A8 (en) | 2003-09-22 |
| EP1585962A2 (en) | 2005-10-19 |
| CA2478036A1 (en) | 2003-09-18 |
| AU2003217954A1 (en) | 2003-09-22 |
| US20050170352A1 (en) | 2005-08-04 |
| WO2003076896A3 (en) | 2006-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050095611A1 (en) | Identification of biomarkers for detecting pancreatic cancer | |
| US7605003B2 (en) | Use of biomarkers for detecting ovarian cancer | |
| JP6010597B2 (ja) | 卵巣癌用のバイオマーカー | |
| US8682591B2 (en) | Biomarkers for ovarian cancer | |
| US20140155293A1 (en) | Identification of biomarkers for detecting prostate cancer | |
| US20140038837A1 (en) | Biomarkers for the detection of early stage ovarian cancer | |
| US7951529B2 (en) | Biomarkers for breast cancer | |
| JP2006508326A (ja) | 乳癌を検出するためのバイオマーカーの使用 | |
| JP2016212116A (ja) | 卵巣癌の患者における予後予測バイオマーカー | |
| US20100068818A1 (en) | Algorithms for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer | |
| US20060257946A1 (en) | Serum biomarkers in ischaemic heart disease | |
| WO2006071843A2 (en) | Biomarkers for breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060306 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060306 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090501 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090513 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090601 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090608 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090702 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090803 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100316 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100611 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100618 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100713 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100721 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101026 |